GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Collegium Pharmaceutical COLL · USD

Health Care · US listing · 🇺🇸 United States

Compare

24.71

+2.07%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$780.6m

FY2016FY2025

Net income

$62.9m

FY2016FY2025

Free cash flow

$327.6m

FY2016FY2025

Shareholders' equity

$301.7m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$780.6m$631.4m$566.8m$463.9m$276.9m$310.0m$296.7m$280.4m$28.5m$1.7m
Research and development———$4.0m$9.5m$9.8m$10.3m$8.7m$8.6m$14.9m
Operating income$163.6m$172.5m$143.5m$33.3m$17.6m$56.2m−$23.7m−$20.7m−$75.4m−$94.1m
Net income$62.9m$69.2m$48.2m−$25.0m$71.5m$26.8m−$22.7m−$39.1m−$74.9m−$94.2m
Diluted earnings per share1.581.731.15-0.742.100.76-0.68-1.16-2.28-3.48

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$1.66bn$1.66bn$1.14bn$1.17bn$692.1m$643.8m$306.3m$291.2m$135.6m$162.0m
Cash and short-term investments$406.5m$162.8m$310.5m$173.7m$186.4m$174.1m$170.0m$146.6m$118.7m$153.2m
Total liabilities$1.36bn$1.43bn$947.9m$979.3m$489.1m$457.8m$218.9m$199.7m$31.5m$27.1m
Debt$810.7m$852.5m$667.2m$701.0m$250.0m$257.1m$11.5m$11.5m$1.5m$4.2m
Shareholders' equity$301.7m$228.8m$195.4m$194.8m$202.9m$186.0m$87.4m$91.6m$104.1m$134.9m
Shares outstanding40m40m42m34m34m35m34m34m33m27m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations$329.3m$205.0m$274.7m$124.2m$103.6m$93.9m$27.8m$169.4m−$67.0m−$75.1m
Capital spending−$1.7m−$1.7m−$461,000−$1.6m−$1.9m−$373.8m−$6.4m−$24.4m−$990,000−$3.0m
Free cash flow$327.6m$203.3m$274.3m$122.6m$101.6m−$279.8m$21.3m$145.0m−$68.0m−$78.0m
Dividends paid——−$9.1m—−$12.7m−$7.3m——−$736,000−$24.6m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$199.9m$193.5m$205.4m$209.4m$188.0m$177.8m$181.9m$159.3m
Operating income$3.7m$32.0m$59.2m$63.6m$35.1m$23.9m$38.1m$34.8m
Net income−$15.1m$14.5m$17.0m$31.5m$12.0m$2.4m$12.5m$9.3m
Diluted earnings per share-0.460.450.430.790.300.060.310.23
Cash from operations$71.0m$57.0m$123.0m$78.0m$72.0m$55.0m$84.0m−$8.0m
Total assets$2.14bn$1.65bn$1.66bn$1.61bn$1.59bn$1.63bn$1.66bn$1.64bn
Cash and short-term investments$129.5m$421.8m$406.5m$305.7m$222.2m$197.8m$162.8m$120.0m
Debt$1.09bn$804.3m$810.7m$809.5m$824.3m$839.0m$853.8m$868.5m
Shareholders' equity$311.9m$312.4m$301.7m$274.8m$232.2m$234.4m$228.8m$234.3m

Financial ratios

Data as of 3 Nov 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Operating margin22.4%27.3%28.1%7.4%6.4%18.2%———
Net margin8.1%11.0%8.5%-5.4%25.8%8.6%———
Return on equity20.8%30.2%24.6%-12.8%35.2%14.4%———
Return on assets3.8%4.2%4.2%-2.1%10.3%4.2%———
Free cash flow yield35.2%21.8%27.8%15.8%13.1%55.8%———
Revenue growth23.6%11.4%22.2%67.6%-10.7%4.5%———
Earnings growth-9.1%43.7%-292.6%-135.0%167.3%-217.7%———
Current ratio1.57x0.95x1.17x0.97x1.13x1.16x———
Debt to equity2.69x3.73x3.42x3.60x1.24x1.39x———
Equity ratio18.2%13.8%17.1%16.6%29.3%28.9%———
Interest coverage2.13x2.33x1.91x0.54x0.84x1.95x———
R&D as a share of sales———0.9%3.4%3.2%3.5%3.1%30.1%
Buybacks as a share of market value1.0%4.0%-24.4%1.6%3.7%-5.4%———

Growth per year

Compound annual rate

3 years5 years10 years
Revenue18.9%20.3%—
Operating income70.0%23.8%—
Net income—18.6%—

Average margins

Over each period

1 year3 years5 years10 years
Operating margin23.8%21.0%19.4%—
Net margin9.4%6.4%8.4%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings29.216.626.7-31.28.926.5-30.4-14.8-8.1-4.5
Price to sales2.41.82.31.72.32.32.32.121.3246.6

Market value over time

30 Dec 2016 to 2 Nov 2026, in USD

$358.1m$768.7m

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return64%0%31%21%3%-7%23%-12%6%-35%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.